Circulating tumor DNA biomarkers for response assessment in prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research（2023）
摘要
Circulating tumor DNA (ctDNA) is measurable in the majority of metastatic castrate-resistant prostate cancer patients. Data indicate that ctDNA present at baseline can serve as a prognostic biomarker and changes in the ctDNA post-treatment can rapidly predict both time to progression and survival.
更多查看译文
关键词
tumor dna biomarkers,prostate cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要